CD19 and neoplasm: Despite the unprecedented efficacy of CD19-CAR T cell therapy, a number of patients still experience relapses due to heterogeneous CD19 expression in the tumor cells, leading to outgrowths of therapy-resistant tumor variants that have lost or downregulated CD19 expression [3].